Subject and method: A descriptive study of 53 patients with stage II-III upper third esophageal carcinoma whom underwent curative chemoradiation regimen 60Gy/28 fractions and paclitaxel / carboplatin infusion weekly at Department of Radiation Oncology and Radiosurgery, 108 Military Central Hospital from May 2017 to January 2021.